152 related articles for article (PubMed ID: 34860497)
1. Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6.
Cao Z; Gu Z; Lin S; Chen D; Wang J; Zhao Y; Li Y; Liu T; Li Y; Wang Y; Lin H; He B
ACS Chem Biol; 2021 Dec; 16(12):2746-2751. PubMed ID: 34860497
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release.
Bockstiegel J; Wurnig SL; Engelhardt J; Enns J; Hansen FK; Weindl G
Biochem Pharmacol; 2023 Sep; 215():115693. PubMed ID: 37481141
[TBL] [Abstract][Full Text] [Related]
3. Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation.
Chen P; Zhao LJ; Huang L; He WQ; Tang YR; Liu Y; Ren JD
Inflamm Res; 2023 Sep; 72(9):1919-1932. PubMed ID: 37725105
[TBL] [Abstract][Full Text] [Related]
4. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
[TBL] [Abstract][Full Text] [Related]
5. Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties.
Kraft FB; Enns J; Honin I; Engelhardt J; Schöler A; Smith ST; Meiler J; Schäker-Hübner L; Weindl G; Hansen FK
Bioorg Chem; 2024 Feb; 143():107072. PubMed ID: 38185013
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase 6 negatively regulates NLRP3 inflammasome activation.
Hwang I; Lee E; Jeon SA; Yu JW
Biochem Biophys Res Commun; 2015 Nov; 467(4):973-8. PubMed ID: 26471297
[TBL] [Abstract][Full Text] [Related]
7. The Role of HDAC6 in Autophagy and NLRP3 Inflammasome.
Chang P; Li H; Hu H; Li Y; Wang T
Front Immunol; 2021; 12():763831. PubMed ID: 34777380
[TBL] [Abstract][Full Text] [Related]
8. The lysosomal Ragulator complex activates NLRP3 inflammasome in vivo via HDAC6.
Tsujimoto K; Jo T; Nagira D; Konaka H; Park JH; Yoshimura SI; Ninomiya A; Sugihara F; Hirayama T; Itotagawa E; Matsuzaki Y; Takaichi Y; Aoki W; Saita S; Nakamura S; Ballabio A; Nada S; Okada M; Takamatsu H; Kumanogoh A
EMBO J; 2023 Jan; 42(1):e111389. PubMed ID: 36444797
[TBL] [Abstract][Full Text] [Related]
9. [Inhibition of Histone Deacetylase 6 Ameliorates Podocyte Injury in Diabetic Kidney Disease in Mice].
Hou Q; Kan S; Zhang M; Xu F; Liu Z; Jiang S
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1097-1104. PubMed ID: 38162083
[TBL] [Abstract][Full Text] [Related]
10. Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8.
Sun Z; Deng B; Yang Z; Mai R; Huang J; Ma Z; Chen T; Chen J
Eur J Med Chem; 2022 Sep; 239():114544. PubMed ID: 35759908
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of HDAC6 alleviates ventricular remodeling in experimental dilated cardiomyopathy via inhibition of NLRP3 inflammasome activation and promotion of cardiomyocyte autophagy.
Pang X; Guan Q; Lin X; Chang N
Cell Biol Toxicol; 2023 Oct; 39(5):2365-2379. PubMed ID: 35764897
[TBL] [Abstract][Full Text] [Related]
12. HDAC6/aggresome processing pathway importance for inflammasome formation is context-dependent.
Wang L; Shi S; Unterreiner A; Kapetanovic R; Ghosh S; Sanchez J; Aslani S; Xiong Y; Hsu CL; Donovan KA; Farady CJ; Fischer ES; Bornancin F; Matthias P
J Biol Chem; 2024 Feb; 300(2):105638. PubMed ID: 38199570
[TBL] [Abstract][Full Text] [Related]
13. First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation.
Yue K; Sun S; Jia G; Qin M; Hou X; Chou CJ; Huang C; Li X
J Med Chem; 2022 Sep; 65(18):12140-12162. PubMed ID: 36073117
[TBL] [Abstract][Full Text] [Related]
14. HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation.
Magupalli VG; Negro R; Tian Y; Hauenstein AV; Di Caprio G; Skillern W; Deng Q; Orning P; Alam HB; Maliga Z; Sharif H; Hu JJ; Evavold CL; Kagan JC; Schmidt FI; Fitzgerald KA; Kirchhausen T; Li Y; Wu H
Science; 2020 Sep; 369(6510):. PubMed ID: 32943500
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HDAC6 alleviates cancer‑induced bone pain by reducing the activation of NLRP3 inflammasome.
Hu YD; Wang ZD; Yue YF; Li D; Zhen SQ; Ding JQ; Meng W; Zhu HL; Xie M; Liu L
Int J Mol Med; 2024 Jan; 53(1):. PubMed ID: 37997785
[TBL] [Abstract][Full Text] [Related]
16. Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.
Yang K; Song Y; Xie H; Wu H; Wu YT; Leisten ED; Tang W
Bioorg Med Chem Lett; 2018 Aug; 28(14):2493-2497. PubMed ID: 29871848
[TBL] [Abstract][Full Text] [Related]
17. HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway.
Chen Q; Wang Y; Jiao F; Cao P; Shi C; Pei M; Wang L; Gong Z
J Cell Mol Med; 2021 Aug; 25(15):7218-7228. PubMed ID: 34180140
[TBL] [Abstract][Full Text] [Related]
18. HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury.
Liu L; Zhou X; Shetty S; Hou G; Wang Q; Fu J
Toxicol Appl Pharmacol; 2019 May; 370():178-183. PubMed ID: 30910594
[TBL] [Abstract][Full Text] [Related]
19. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
[TBL] [Abstract][Full Text] [Related]
20. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
